Innoviva, Inc.
NASDAQ:INVA
Overview | Financials
Company Name | Innoviva, Inc. |
Symbol | INVA |
Currency | USD |
Price | 18.32 |
Market Cap | 1,146,852,152 |
Dividend Yield | 0% |
52-week-range | 14.33 - 21.28 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Pavel Raifeld C.F.A. |
Website | https://www.inva.com |
An error occurred while fetching data.
About Innoviva, Inc.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD